Market Place
Sourcing Support
Paratek Ph 2b Data Shows Omadacycline’s Potential in NTM Treatment
15 Nov 2024 //
EXPRESSPHARMA
Paratek Completes U.S. Onshoring for NUZYRA Domestic Supply
14 Nov 2024 //
GLOBENEWSWIRE
Paratek Pharma Positive Phase 2b Omadacycline NTM Data
08 Nov 2024 //
GLOBENEWSWIRE
Paratek Announces Presentation of Studies of Nuzyra at IDWeek 2024
14 Oct 2024 //
GLOBENEWSWIRE
Paratek Completes 5-Year NUZYRA® Surveillance Study
31 Jul 2024 //
GLOBENEWSWIRE
Paratek Reports Positive Data For NUZYRA In Bacterial Pneumonia Study
18 Jul 2024 //
GLOBENEWSWIRE
Paratek Showing NUZYRA, Preclinical Data At ESCMID Global 2024
18 Apr 2024 //
GLOBENEWSWIRE
Paratek Announces Modification of BARDA Contract to Develop NUZYRA
10 Jul 2023 //
GLOBENEWSWIRE
EMA COMP Recommends +ve Opinion on Orphan Medicinal Product Desig. for NUZYRA
27 Jun 2023 //
GLOBENEWSWIRE
Paratek Pharmaceuticals Presenting New Data from NUZYRA
12 Jun 2023 //
GLOBENEWSWIRE
Paratek Presenting Data from NUZYRA and Investigator-Initiated Research Programs
10 Apr 2023 //
GLOBENEWSWIRE
Paratek Receives $36.4 M Milestone Payment NUZYRA (omadacycline)
05 Jan 2023 //
GLOBENEWSWIRE
Paratek Pharma Announces Positive Top Line Data from Pilot Efficacy Study
19 Dec 2022 //
GLOBENEWSWIRE
Paratek Achieves Milestone Creating U.S. Mfg. Supply Chain for NUZYRA
31 Oct 2022 //
CONTRACTPHARMA
Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline)
13 Oct 2022 //
GLOBENEWSWIRE
Novasep & Paratek enhance collaboration to manufacture omadacycline (NUZYRA®)
15 Feb 2022 //
PRESS RELEASE
NMPA Approves NUZYRA as Category 1 Innovative Drug for CABP and ABSSSI
16 Dec 2021 //
PRESS RELEASE
China`s National Medical Products Administration Approves NUZYRA®
16 Dec 2021 //
GLOBENEWSWIRE
PAOG Introduces RelaxRX CBD Targeting $100 Billion Sleep Aid
19 Oct 2021 //
GLOBENEWSWIRE
Paratek PharmaAnnounces Enrollment of First Patient in Phase 2b Study NUZYRA®
18 Oct 2021 //
GLOBENEWSWIRE
Paratek Pharmaceuticals Announces Additional Funding Under the BARDA
27 Sep 2021 //
BIOSPACE
Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline)
23 Sep 2021 //
GLOBENEWSWIRE
Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA®
18 Aug 2021 //
GLOBENEWSWIRE
Paratek Pharmaceuticals Announces Initiation of Phase 2b Study with NUZYRA
16 Jun 2021 //
GLOBENEWSWIRE
Paratek Announces Full Year 2020 Total Revenue of $46.9 M NUZYRA®
24 Feb 2021 //
GLOBENEWSWIRE
Omadacycline, Moxifloxacin Similarly Effective in Legionella pneumophila
26 Oct 2020 //
FIRSTWORDPHARMA
Paratek Pharmaceuticals Presenting New Data on NUZYRA®
22 Oct 2020 //
GLOBENEWSWIRE
Paratek Announces Second Quarter 2020 Total Revenue of $9.3 M including NUZYRA®
10 Aug 2020 //
GLOBENEWSWIRE
Zai Lab Announces NDA for Omadacycline Granted Priority Review by China’s NMPA
06 May 2020 //
GLOBENEWSWIRE
Paratek wins US contract to develop anthrax treatment
21 Dec 2019 //
BIOPHARMA DIVE
Paratek Pharma reports positive results from phase 2 studies
03 Nov 2019 //
PHARMABIZ
Paratek`s top antibiotic fails to clear a key competitive hurdle in head-to-head studies
02 Nov 2019 //
ENDPTS
Paratek +5.5% on withdrawing Europe application for Nuzyra
17 Oct 2019 //
SEEKINGALPHA
The Lancet Infectious Diseases Publishes Results Paratek’s Ph3 Oral only NUZYRA
02 Sep 2019 //
INVESTOR
Paratek publishes positive PhIII data on approved Nuzyra
31 Aug 2019 //
ENDPOINT NEWS
MMS Submission Support for Paratek Pharmaceuticals` Omadacycline
11 Oct 2018 //
PR NEWSWIRE
MMS Submission Support for Paratek Pharmaceuticals` Omadacycline
11 Oct 2018 //
PR NEWSWIRE
MMS Submission Support for Paratek Pharmaceuticals` Omadacycline
11 Oct 2018 //
PR NEWSWIRE
Paratek enters commercial stage with 2 FDA antibiotics nods
03 Oct 2018 //
FIERCE PHARMA
Paratek caps 20-year R&D journey with FDA OK for its broad spectrum antibiotic
03 Oct 2018 //
ENDPTS
Green light for acne drug Seysara in the US
03 Oct 2018 //
PHARMA TIMES
Paratek antibiotic not inferior to current treatments: FDA staff
06 Aug 2018 //
REUTERS
2018 Meeting Materials, Antimicrobial Drugs Advisory Committee
03 Aug 2018 //
FDA
Paratek Announces FDA Advisory Committee Date for Omadacycline
20 Jun 2018 //
PRESS RELEASE
Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies
11 Jun 2018 //
PRESS RELEASE
Paratek Demonstrates Breadth of Omadacycline Clinical & Microbio Data at ASM
07 Jun 2018 //
PRESS RELEASE
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
01 Jun 2018 //
PRESS RELEASE
Paratek Presents New Analysis Highlighting Efficacy of Omadacycline
22 May 2018 //
PRESS RELEASE
Paratek Presents Data Supporting Potential Approval of Omadacycline
23 Apr 2018 //
PRESS RELEASE
Paratek Prices $140 M of Convertible Senior Subordinated Notes due 2024
19 Apr 2018 //
PRESS RELEASE
Paratek Announces Proposed Private Offering of $125 M
18 Apr 2018 //
PRESS RELEASE
Paratek’s NDA for Oral & IV Omadacycline Accepted for Priority Review FDA
04 Apr 2018 //
PRESS RELEASE
Paratek Provides Update on Pipeline Progress
03 Jan 2018 //
PRESS RELEASE
